Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1500)	5/25/2004 2:15:17 PM
From: Ward Knutson	Respond to of 1826

>>A simply amazing launch given only about 100 salespeople.<< 100 people in the field - oncology focused - is essentially as strong as any presence from Amgen, Glaxo, Aventis, and Roche. An interesting point: quite a few MGI field personnel were plucked from Amgen in preparation for the launch of Aloxi; and of course the initial commercial expansion, back in late 1999 into early 2000, brought numerous key people from Aventis. Most of us longterm MGI lemmings saw this coming all along... :-)